Supportive Care for Infants with Pertussis

Immediate Assessment and Monitoring

Infants under 12 months with suspected pertussis should be hospitalized for continuous cardiorespiratory monitoring due to the high risk of severe and life-threatening complications, including apneic spells, bradycardia, cyanosis, and death, as recommended by the Centers for Disease Control and Prevention 1, 2
Continuous pulse oximetry and apnea monitoring are crucial, as infants can present with apneic spells and minimal cough initially, with a strength of evidence level of high 1, 2
Respiratory status assessment between paroxysms is essential, as infants typically appear well between episodes despite severe disease, with a moderate level of evidence 1, 2

Frequent small feedings should be provided to prevent aspiration and maintain nutrition, as post-tussive vomiting leads to substantial weight loss and feeding difficulties, as recommended by the American Academy of Pediatrics 1, 2
Smaller, more frequent feeds should be offered immediately after coughing episodes when the infant is less likely to cough, with a low level of evidence 1, 2
Nasogastric or intravenous hydration should be considered if vomiting is severe enough to cause dehydration or significant weight loss, with a moderate level of evidence 1, 2

A calm, quiet environment should be maintained to minimize coughing triggers, as paroxysms can be precipitated by stimulation and occur more frequently at night, as recommended by the Centers for Disease Control and Prevention 1, 2
Environmental irritants and tobacco smoke exposure should be reduced, with a high level of evidence 3
Adequate humidification of inspired air should be ensured, with a moderate level of evidence 1, 2

Macrolide antibiotics, preferably azithromycin, should be initiated immediately when pertussis is suspected to prevent transmission to contacts, even though antibiotics started after the catarrhal stage will not significantly alter the clinical course, as recommended by the Infectious Diseases Society of America 3, 4
Erythromycin is effective in eliminating the organism from the nasopharynx and reducing transmission, with a high level of evidence 4

Infants should be monitored closely for complications that result from severe coughing pressure, including pneumothorax, subconjunctival hemorrhage, subdural hematoma, and seizures, as recommended by the American Academy of Pediatrics 1, 2
Signs of secondary bacterial pneumonia or otitis media should be watched for, with a moderate level of evidence 1, 2
Neurologic complications, including seizures and hypoxic encephalopathy, should be assessed, with a high level of evidence 1, 2

Significant sleep disturbance should be expected and planned for, as paroxysms occur more frequently at night and patients often have substantial sleep disruption, as recommended by the American Academy of Sleep Medicine 1, 2, 3
Continuous monitoring allows for immediate intervention during nocturnal paroxysms, with a high level of evidence 1, 2
The infant should be positioned safely for sleep while facilitating secretion drainage, with a moderate level of evidence 1, 2

Infants under 12 months should not be discharged prematurely, as the paroxysmal stage typically lasts 2-6 weeks and complications can occur throughout, as recommended by the Centers for Disease Control and Prevention 1, 2
The infant's appearance between paroxysms should not be assumed to indicate improvement, as they often appear relatively well between episodes despite severe disease, with a moderate level of evidence 1, 2

Paroxysmal cough lasting more than two weeks accompanied by cyanosis, facial flushing, and post‑tussive vomiting—especially when preceded by a one‑week catarrhal phase with clear rhinorrhea—are the cardinal clinical features that define pertussis in infants. 5, 6
An inspiratory “whoop” (stridor) that follows cough paroxysms is a characteristic sign of pertussis. 5

Empiric macrolide therapy (azithromycin or erythromycin) should be started immediately upon clinical suspicion of pertussis, without awaiting laboratory confirmation. 5, 6
Recommended pediatric dosing is 40–50 mg/kg per day of erythromycin (or azithromycin, which has a more favorable adverse‑effect profile) for a total of two weeks. 5, 6
Early treatment, even when initiated after the catarrhal phase, rapidly eradicates Bordetella pertussis from the nasopharynx and prevents onward transmission, although it may not markedly change the overall clinical course. 5, 6
Initiating therapy within the first two weeks of the catarrhal phase reduces the severity of subsequent cough paroxysms and lowers the risk of complications. 5, 6
Do not delay treatment while awaiting laboratory results; postponement increases the likelihood of severe complications and disease spread. 5, 6

The only definitive method to confirm pertussis is culture of B. pertussis obtained from a nasopharyngeal aspirate or a Dacron swab. 5, 6
Polymerase‑chain reaction (PCR) testing is available but is not recommended as a standard diagnostic tool because no universally accepted and validated PCR protocol exists. 5, 6

Patients should be placed in isolation for five days after the initiation of appropriate antibiotic therapy. 5
Close contacts—particularly other infants and household members—must be identified and given macrolide prophylaxis to prevent secondary cases. 5